Results 21 to 30 of about 8,068 (200)
Inclusion-Body Myositis Associated with Alzheimer’s Disease
Sporadic inclusion-body myositis (s-IBM) is a myopathy that is characterized by progressive weakness and muscle pathology demonstrating inflammation and rimmed vacuoles.
Danijela Levacic +4 more
doaj +1 more source
Inclusion body myositis – pathomechanism and lessons from genetics
Inclusion body myositis is a rare, late-onset myopathy. Both inflammatory and myodegenerative features play an important role in their pathogenesis.
Murnyák Balázs +8 more
doaj +1 more source
This article addresses the clinical presentation, diagnostic workup, and management of patients with inclusion body myositis (IBM). It also provides an overview of the clinical trial landscape and explores future directions in the pursuit of an effective treatment for the disease.Muscle biopsy remains the cornerstone of the diagnosis, and cytosolic ...
Warman-Chardon, Jodi +2 more
openaire +4 more sources
An efficient radiosynthesis of fluorine‐18 labeled gluconic acid ([18F]FGA) was developed using two readily available materials, 2‐deoxy‐2‐[18F]fluoro‐D‐glucose ([18F]FDG) and glucose oxidase. [18F]FGA is highly specific for bacterial gluconate metabolism mediated by gluconate permease (GntP) and gluconate kinase (GntK), with rapid clearance, low off ...
Sang Hee Lee +7 more
wiley +2 more sources
. Previous studies have reported elevated cardiac troponin T (cTnT) in patients with inclusion body myositis due to skeletal myopathy. Although the trends of cTnT have been reported in some cases, the onset of elevation has barely been reported.
Zhiqing Fu, Xiujin Zhang, Hanjia Gao
doaj +1 more source
Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis
Objective: Sporadic Inclusion Body Myositis (sIBM) is an inflammatory myopathy (IIM) without a specific diagnostic biomarker until autoantibodies to the cytosolic 5′-nucleotidase 1A (NT5c1A/Mup44) were reported.
Adam Amlani +11 more
doaj +1 more source
Update in inclusion body myositis [PDF]
The purpose of this study is to review recent scientific advances relating to the natural history, cause, treatment and serum and imaging biomarkers of inclusion body myositis (IBM).Several theories regarding the aetiopathogenesis of IBM are being explored and new therapeutic approaches are being investigated. New diagnostic criteria have been proposed,
Machado, P, Brady, S, Hanna, MG
openaire +3 more sources
Objective This research article aims to describe the prevalence, associations, and health‐related quality of life (HRQoL) impact of mucocutaneous features of systemic lupus erythematosus (SLE). Methods Data from the Asia‐Pacific Lupus Collaboration cohort were analyzed (2013–2021).
Amanda M. Saracino +42 more
wiley +1 more source
Objective The aim of this study was to determine the differences in demographic, serologic, and clinical characteristics between male and female patients with systemic sclerosis (SSc) in an Australian cohort. Methods This was a retrospective observational study using data from the Australian Scleroderma Cohort Study.
Emily Lin +14 more
wiley +1 more source
Asymptomatic hyper-creatine-kinase-emia as sole manifestation of inclusion body myositis
Sporadic inclusion body myositis (sIBM) usually manifests with painless weakness of the hand, finger and hip flexors. Absence of symptoms or signs, but mild hyper-CK-emia as the sole manifestation of IBM, has not been reported. We report the case of a 73-
Josef Finsterer +2 more
doaj +1 more source

